Illumina, Inc. $ILMN Shares Bought by ASR Vermogensbeheer N.V.

ASR Vermogensbeheer N.V. grew its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 7.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 220,076 shares of the life sciences company’s stock after acquiring an additional 14,397 shares during the quarter. ASR Vermogensbeheer N.V. owned about 0.14% of Illumina worth $20,997,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Illumina by 3.5% in the first quarter. Vanguard Group Inc. now owns 16,371,662 shares of the life sciences company’s stock worth $1,298,928,000 after buying an additional 558,243 shares during the period. WCM Investment Management LLC boosted its position in shares of Illumina by 1.2% in the first quarter. WCM Investment Management LLC now owns 4,179,011 shares of the life sciences company’s stock worth $334,321,000 after buying an additional 49,156 shares during the period. Corvex Management LP boosted its position in shares of Illumina by 125.2% in the first quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company’s stock worth $303,841,000 after buying an additional 2,129,449 shares during the period. Brown Advisory Inc. boosted its position in shares of Illumina by 52.1% in the first quarter. Brown Advisory Inc. now owns 2,909,228 shares of the life sciences company’s stock worth $230,818,000 after buying an additional 996,589 shares during the period. Finally, AQR Capital Management LLC boosted its position in shares of Illumina by 361.7% in the first quarter. AQR Capital Management LLC now owns 2,121,585 shares of the life sciences company’s stock worth $165,484,000 after buying an additional 1,662,093 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ILMN. Stephens set a $110.00 price objective on Illumina and gave the company an “overweight” rating in a research note on Monday, August 4th. Canaccord Genuity Group raised their price objective on Illumina from $99.00 to $105.00 and gave the company a “hold” rating in a research note on Friday, August 1st. Barclays raised their price objective on Illumina from $85.00 to $90.00 and gave the company an “underweight” rating in a research note on Friday, August 1st. Scotiabank lowered Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 price objective for the company. in a research note on Friday, July 11th. Finally, Wall Street Zen lowered Illumina from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Six research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $123.06.

Illumina Stock Up 7.7%

Shares of ILMN stock opened at $102.26 on Thursday. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The stock has a market cap of $15.72 billion, a PE ratio of 12.94, a price-to-earnings-growth ratio of 2.29 and a beta of 1.40. The business’s fifty day moving average is $99.38 and its 200-day moving average is $89.64. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.17. The company had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm’s revenue for the quarter was down 4.8% on a year-over-year basis. During the same period last year, the firm earned $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Equities analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.